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to visually represent determinants of post-HCT morbidity,
along with the direct and indirect contributing factors.
Methods, Intervention, & Analysis: A literature synthesis,
supplemented with clinical expertise from HCT care teams,
informed the construction of this evidence-based concep-
tual model. The model displays the working relationships
between indirect contributing factors, direct contributing
factors, and immediate determinants of post-HCT morbidity.
Findings & Interpretation: Four main determinants were
found to result in post-transplant morbidity: Malnutritive
state, infection, organ disease/failure, and malignancy. Nine
direct- and seventeen indirect-factors have been shown to
contribute to these determinants.
Discussion & Implications: The model is intended for use
by future nurse researchers to identify opportunities for tar-
geted interventions aimed at improving post-HCT morbidity.
In addition, the model may be used as an educational tool
for HCT recipients and their families to explain risks, build
trust, and evolve understanding of the HCT process.
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Topic Significance & Study Purpose/Background/Rationale:
searching information is one the most used resource for
coping of the illness experience provided empowerment and
decision making for the family to the illness situation. Con-
sidering the potential of virtual environment for health
information dissemination allied to the context of hemato-
poietic stem cell transplantation (HSCT), it is indispensable
to innovate this field, proposing the use of new technology
information. Our objective was to design, develop, and test
the usability and satisfaction of an informative mobile ap-
plication for families of children or adolescents with cancer
who are undergoing HSCT.
Methods, Intervention, & Analysis: The Patient-and Family-
Centered Care Model and User-Centered Design constituted
the theoretical framework of this methodological study. An
integrative review of the literature, a qualitative field study
to identify the family’s needs for information, and a biblio-
graphical study were conducted for the development of the
software application prototype. Subsequently, content vali-
dations were carried out with experts and the target
population, and finally a usability evaluation conducted by
information technology specialists. In the end, a qualitative
case studywas conducted to evaluate usability from the family
perspective.
Findings & Interpretation: The prototype TMO-App has 268
screens and 95 illustrations. Information needs were taken
into account to develop the prototype, subsequently vali-
dated by specialists, with over 80% agreement, and by end
users, who endorsed the application’s potential to mitigate
the suffering experienced by family members. In the vali-
dated by target population, a global content value index of
0,98 was obtained. Because usability severity was rated by
experts as simple, the application was given a final version
and interactively tested with a family, whose members sub-
sequently acknowledged feeling strengthened by the
information thus acquired, which enabled them to cope with
the experience of having a child undergoing HSCT.
Discussion & Implications: The study provides advance-
ment in proposing new informative strategies for family
empowerment in situations of chronic illness. Evidence was
also provided on the recognition of user needs as essential
to the design and implementation of new technologies. The
TMO-App application software is a potential strategy to serve
the families of children/adolescents with cancer submitted
to HSCT in their right to information, facilitating their coping
process in a strengthened way.
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Topic Significance & Study Purpose/Background/Rationale:
Advances in stem cell transplant have increased the
long-term survival rate of our patient population. Allogene-
ic SCT-associated bone loss is usually described in the first
6-12 months following the transplant. Pre- transplant che-
motherapy, conditioning regimens, graft vs. host disease
prophylaxis, glucocorticoid use, older age, and genetic factors
all play a role in bone loss. We analyzed 45 patients retro-
spectively pre- transplant and one year post transplant and
identified the percentage of bone loss using bone mineral
density measured in g/m2.
Methods, Intervention, & Analysis: We looked at 45 pa-
tients pre- transplant and one year post transplant. To
determine percentage of bone loss, we reviewed DEXA
scans all performed at Siteman Cancer Center through the
Washington University Bone and Mineral Division. We
looked at bone mineral density (g/m2) at L1-4 and femoral
head.
Findings & Interpretation: We found a significant differ-
ence at one year post transplant in the DEXA scan scores.
There was a statistically significant difference in osteopenia/
osteoporosis in patients who have undergone transplantation.
Discussion & Implications: Significant loss of bone mineral
density post transplantation leads to the need for more clin-
ical trials looking atmedications that can prevent further bone
loss in this patient population. We need clear guidelines for
the screening, prevention and treatment of bone loss fol-
lowing stem cell transplant.
Figure 1. Origins of post-transplant morbidity model.
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